Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, et al. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther 2021 Oct 25. doi: 10.1111/apt.16663.
PMID: 34694009